Chinese ADCs and Bispecific Antibodies Going Global: Cutting-Edge Advances in Breast Cancer and Esophageal Cancer Clinical Trials

By HongKong DengYue Medicine

On the global battlefield against cancer, Chinese innovative drugs are rapidly integrating into the international stage, offering more precise treatment options to countless patients. As someone who has long battled breast cancer, I deeply understand the longing for new therapies—when conventional treatments fail, a drug that can precisely target tumors may be the turning point for reclaiming life. In recent years, breakthroughs by Chinese companies in the fields of ADCs (antibody-drug conjugates) and bispecific antibodies have not only demonstrated potential in domestic clinical trials but are also expanding worldwide through international licensing deals and multi-center studies, helping more people fight stubborn diseases. Below, we examine several representative drugs from the perspectives of therapeutic targets, mechanisms of action, and clinical data, showing how they started in China and are now reaching the world.

These advances stem from the continuous deep investment by Chinese pharmaceutical companies in oncology and autoimmune diseases. Take breast cancer as an example: more than 2 million new cases are diagnosed globally each year, and many patients face resistance after endocrine therapy. Chinese innovative drugs such as HRS-8080 are providing new options by targeting the ER (estrogen receptor) pathway. In the digestive tract tumor field, patients with esophageal adenocarcinoma often have poor prognosis, but ADC drugs like LM-302, with their efficient toxin delivery capability, are bringing new hope. These drugs are no longer confined to the laboratory; they have already been validated in clinical trials across China, the US, and other countries, and are accelerating global access through out-licensing deals (e.g., collaborations with GSK, Pfizer, and others).

The following table presents key information on several high-profile drugs for easy reference:

These drugs began in Chinese clinical trials and are now steadily entering the global landscape. For example, the Phase III design of HRS-8080 follows international guidelines and plans to include patient data from Europe and the US; LM-302 is advancing simultaneously in China and the US, targeting digestive tract tumors that are highly prevalent worldwide. Innovent’s IBI3002 is a rising star in the autoimmune field, helping atopic dermatitis patients escape the torment of recurrent flare-ups—imagine no longer suffering from unbearable itching, being able to embrace daily life with peace of mind. That kind of relief is profoundly real.

Of course, these achievements are inseparable from the pursuit of excellence and innovation by pharmaceutical companies. As a company that values sustainable development, Hong Kong DengYue Medicine is always grounded in quality, compliance, and integrity, actively participating in the global market. We believe that by supporting domestic innovative drugs to reach overseas markets, we not only enhance the international influence of Chinese innovation, but also contribute to the health of people worldwide. In the future, as more clinical readouts emerge, these drugs have the potential to reshape global treatment paradigms. If you or someone close to you has had a similar experience, feel free to share your story in the molecularcloud.org community—together, let’s witness the progress.